APDM and OHSU Awarded 3 New Grants from NIH Worth $4.6 M
APDM is pleased to announce it has been awarded 3 grants from the National Institute on Aging and the National Cancer Institute of the National Institutes of Health.
Mobility Life: Phase II SBIR – $2,932,813
Continuous monitoring of mobility in daily lives of people with Neurological Disease.
This study is supported by the National Institute On Aging of the National Institutes of Health under Award Number R44AG055388. It is a collaboration between APDM and the Department of Neurology at Oregon Health & Science University (OHSU).
At the completion of the proposed work for this Phase II grant, APDM and OHSU will have the first system that can continuously measure mobility, characterize turning and balance during continuous monitoring of subjects in and outside the home, and assess fall risk. APDM and OHSU will also create the first wirelessly-synchronized ankle wrap, instrumented with inertial sensors to monitor gait and foot movements. Mobility Life will be suitable for use in medical applications to assess mobility fluctuations, response to medication, and disease progression in people with neurological disorders such as Parkinson’s disease (PD) and multiple sclerosis (MS).
The outcome of this project will provide better clinical decisions and improved quality of life for people with impaired mobility due to neurological disorders. The system will also be of importance for clinical researchers by enabling them to determine the efficacy of interventions on actual functional performance in daily life.
Mobility Clinic: Phase II – $1,457,589
A Wearable System for Assessment of Fall Risk Associated with Cancer Treatment.
This study is supported by the National Cancer Institute of the National Institutes of Health under Award Number HHSN261201600067C. It is a collaboration between APDM and the OHSU School of Nursing, which has been consistently ranked among the top 10 nursing schools in the United States by US News and World Report.
The ultimate goal for this project is to develop a portable clinical system to quickly and automatically obtain objective measures of balance and gait impairments and to evaluate fall risk in cancer subjects using unobtrusive, wearable sensors. The outcome of Mobility Clinic will provide better clinical decisions and improved quality of life for cancer subjects at risk of falling due to cancer treatment.
To determine the clinical utility of Mobility Clinic, data will be collected on two patient populations that span the spectrum of the cancer trajectory when subjects are at risk of falls. The first population is post-treatment, community-dwelling cancer survivors where persistent side effects and symptoms lead to increased falls beyond the risk imposed by aging. This includes over 400 post-treatment female cancer survivors from the OHSU fall prevention clinical trial, called GET FIT. The second population includes over 100 inpatient bone marrow transplant subjects who are at high risk of falls during the 1-month hospital stay due to aggressive cytotoxic and immunosuppressive therapies.
In addition to the clinical study, this contract will allow APDM to expand the functionality of its Mobility Exchange data management system through a web-based interface to allow registered users to remotely access and analyze data from collaborating clinical sites.
Mobility Rehab: Phase I – $298,607
Mobility Rehab: A Biofeedback System for Mobility Rehabilitation for Older Adults
This study is supported by the National Institute On Aging of the National Institutes of Health under Award Number R43AG056012. It is a collaboration between APDM, the Department of Neurology at Oregon Health & Science University (OHSU), and the Balance Disorders Laboratory, a world class gait and balance disorders research program at OHSU, Directed by APDM Chief Scientist Dr. Fay Horak.
The objective of this Phase I grant is to demonstrate the feasibility of an overground, gait biofeedback system for PTs to provide biofeedback for mobility training of older adults with gait impairments. In addition to feedback, the system, called Mobility Rehab, will enable clinicians to measure progress with objective and validated metrics and document the effectiveness of rehabilitation to facilitate reimbursement of their therapy services.
APDM’s goal in Phase II is to optimize Mobility Rehab for personalized rehabilitation with visual and auditory feedback, conduct a clinical trial to evaluate the effectiveness of Mobility Rehab on gait training in older adults with a variety of gait impairments during regular 6-week outpatient rehabilitation program, and to prepare the system for a commercial launch into the clinical market.
The content of this release is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.